Shearman & Sterling advised Equistone Partners Europe (Equistone) on the acquisition financing of a majority stake in Omnicare, a pharmaceutical wholesaler operating throughout Germany that primarily distributes finished medicinal products to compounding pharmacies for the patient-specific production of cancer drugs.
Omnicare was founded in 2002 as a pharmaceutical wholesaler supplying specialized pharmacies throughout Germany. Since 2012, it has been working as a cooperation company for pharmacies producing cytostatic drugs to maintain and secure the future of outpatient oncology in Germany.
Equistone Partners Europe is one of the leading European equity investors with a team of more than 40 investment professionals in six offices in Germany, Switzerland, the Netherlands, France and the United Kingdom. Above all, Equistone invests in established medium-sized companies with good market positions, above-average growth potential and an enterprise value of between €50 and €500 million.
Shearman & Sterling regularly advises Equistone on financing matters, most recently in February 2019 on the financing of the acquisition of RENA.